Rituximab and mycophenolate mofetil (MMF) may be the most effective off-label options for neuromyelitis optica spectrum disorder (NMOSD) patients who are unable to access approved therapies, often due to high costs or limited availability, according to a study in China. The study compared the safety and efficacy of four immunosuppressive…
mycophenolate mofetil
A severe attack or a higher annual relapse rate before starting azathioprine or mycophenolate mofetil (MMF) was associated with a poor response in people with neuromyelitis optica spectrum disorder (NMOSD), a small study shows. An unsatisfactory response to either treatment, defined as a severe relapse or two or more…
Eye scans of people with neuromyelitis optica spectrum disorder (NMOSD) revealed they may have a thicker retina — the eye’s light-detector — and more blood vessels than people with myelin oligodendrocyte glycoprotein antibody disease (MOGAD). That’s according to a study in which researchers used two noninvasive imaging techniques,…
Rituximab may be a more effective immunosuppressive therapy for preventing a first relapse in people with neuromyelitis optica spectrum disorder (NMOSD) than mycophenolate mofetil (MMF), a new meta-analysis found. The anti-CD20 antibody rituximab, commonly used off-label in NMOSD, also appears to work better than azathioprine, though the results failed…